Promega, JA6101, CD28 Blockade Bioassay

Measure Potency and Stability of Biologics Designed to Block CD28 Interactions
96- and 384-well plate compatible
Prequalified according to ICH guidelines
No primary cell culture required
Available in convenient thaw-and-use format
Specifications：
TCR/CD3 Effector Cells (IL-2) J129A 1 × 0.8ml
aAPC/Raji Cells J159A 1 × 0.8ml
Fetal Bovine Serum J121A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
TCR/CD3 Effector Cells (IL-2) J129A 5 × 0.8ml
aAPC/Raji Cells J159A 5 × 0.8ml
Fetal Bovine Serum J121A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
TCR/CD3 Effector Cells (CPM) (IL-2) J127A 2 × 1ml
aAPC/Raji Cells (CPM) J148A 2 × 1ml
Control Ab, Anti-CD28 K123A 1 × 1 each
The CD28 Blockade Bioassay is a bioluminescent cell-based assay used to measure the potency and stability of ligands or antibodies that bind and block CD28/B7 family members, CD80 and CD86 (collectively referred to as B7 for this bioassay). CD28 binds to B7 on antigen-presenting cells (APCs). Co-stimulation of T cells by CD28 activation initiates signaling cascades that result in AP-1 and NFκB transcription factor activation and nuclear translocation. These pathways significantly enhance T cell cytokine production—specifically, interleukin-2 (IL-2)—which promotes T cell proliferation, differentiation and survival.
Blockade of CD28 has proven beneficial in preclinical and clinical studies to reduce autoimmunity and alloimmunity. The CD28 Blockade Bioassay reflects the mechanism of action (MOA) of biologics designed to block the interaction of CD28 with its B7 family ligands.